Akebia Therapeutics
AKBA
96 hedge funds and large institutions have $20.2M invested in Akebia Therapeutics in 2022 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 17 increasing their positions, 34 reducing their positions, and 49 closing their positions.
226% more call options, than puts
Call options by funds: $212K | Put options by funds: $65K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13.49% less ownership
Funds ownership: 44.82% → 31.33% (-13%)
23% less funds holding
Funds holding: 124 → 96 (-28)
50% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 34
51% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 49
65% less capital invested
Capital invested by funds: $58.3M → $20.2M (-$38.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$3.08M |
| 2 |
Millennium Management
New York
|
+$1.14M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$779K |
| 4 |
HF
HRT Financial
New York
|
+$453K |
| 5 |
E
Ergoteles
New York
|
+$356K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$4.58M |
| 2 |
BlackRock
New York
|
-$4.04M |
| 3 |
JP Morgan Chase
New York
|
-$1.78M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$791K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$644K |
AKBA Hedge Fund Activity: Q2 2022 in Review
96 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q2 2022, worth a combined $20.2M — down 65% from $58.3M a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of AKBA and 24 opened new positions — a net loss of 25 holders — while 34 trimmed existing stakes and 17 added.
The largest buyer was Acadian Asset Management, opening a new position worth an estimated $3.08M. The largest seller was State Street, cutting an estimated $4.58M.
- 96 institutional investors held Akebia Therapeutics (AKBA) as of Q2 2022, down from 124 in Q1 2022.
- Funds reported $20.2M of Akebia Therapeutics stock for Q2 2022, down 65% quarter-over-quarter.
- 24 funds opened new Akebia Therapeutics positions in Q2 2022 and 49 closed out, a net change of -25 holders.
- The largest Akebia Therapeutics buyer in Q2 2022 was Acadian Asset Management, an estimated $3.08M added.
- The largest Akebia Therapeutics seller in Q2 2022 was State Street, an estimated $4.58M sold.
Based on aggregated 13F filings for Q2 2022.